Search clinical trials for: Empagliflozin

Total 925 results

Brigham and Women's Hospital
Patient-Centered Outcomes Research Institute; McGill University; VA Boston Healthcare...

Active, not recruiting

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study (CER-4-T2D)

Type2 Diabetes | Renal Disease | Cardiovascular Events

United States
Getz Pharma

Recruiting

Effect of Oral Anti-diabetic Medication on Liver Fat in Subjects With Type II Diabetes and Non-alcoholic Fatty Liver

Diabetes Mellitus, Type 2 | NAFLD | NASH - Nonalcoholic Steatohepatitis

Pakistan
General and Teaching Hospital Celje

Completed

Novel Therapeutics and Endothelial Dysfunction in T1DM Patients (ENDIS)

Diabetes Mellitus, Type 1 | Biomarkers | Endothelial Dysfunction | Arterial Stiffness | FMD | Incretins | Endothelial Progenitor Cells | SGLT 2 Inhibitors | Glucose Excursions | FPF

Slovenia
Chungbuk National University Hospital

Active, not recruiting

Empagliflozin-based Quadruple Therapy vs Basal Insulin-based Therapy (LUCID)

Diabetes Mellitus, Type 2
Saint Luke's Health System

Completed

Empagliflozin Impact on Hemodynamics in Patients With Heart Failure (EMBRACE-HF)

Heart Failure

United States
University of Erlangen-Nürnberg Medical School

Completed

Analysing the Effect of Empagliflozin on Reduction of Tissue Sodium Content in Patients With Chronic Heart Failure (ELSI)

Chronic Heart Failure

Germany
Matthew Neal MD
National Heart, Lung, and Blood Institute (NHLBI)

Active, not recruiting

Accelerating COVID-19 Therapeutic Interventions and Vaccines 4 ACUTE (ACTIV-4A)

Covid19

United States, Spain, Brazil, Italy
University Health Network, Toronto

Recruiting

Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial (NATRIURETIC)

Type 2 Diabetes Mellitus

Canada
University of Sao Paulo General Hospital

Recruiting

SGLT-2 Inhibitors in Prevention of Post-procedural Renal and Cardiovascular Complications aFter PCI Among Patients With Diabetes Mellitus and Coronary Artery Disease: a Prospective, Randomized, Pilot Study (SAFE-PCI) (SAFE-PCI)

Coronary Artery Disease | Diabetes Mellitus, Type 2 | Acute Kidney Injury

Brazil
Yonsei University

Unknown

Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver

Type2 Diabetes | NAFLD - Nonalcoholic Fatty Liver Disease

Korea, Republic of
Zhongshan Hospital Xiamen University

Unknown

Effects of SGLT2 Inhibition Treatment on Different Levels of Albuminuria in Patients With Type 2 Diabetes

Diabetic Nephropathy | Type 2 Diabetes

China
Bio-innova Co., Ltd

Not yet recruiting

Dapagliflozin Tablet 10 mg Relative to Forxiga® Tablets 10 mg (DAP-030-23)

Healthy Subjects
National Taiwan University Hospital
Shin Kong Wu Ho-Su Memorial Hospital

Not yet recruiting

EMPAgliflozin in Heart Failure With PReserved Ejection Fraction and End Stage Renal Disease (EMPA-PRED)

Heart Failure With Preserved Ejection Fraction | End Stage Renal Disease on Dialysis
Dong Wha Pharmaceutical Co. Ltd.

Not yet recruiting

This Study is to Compare and Evaluate the Safety and Pharmacokinetic Characteristics (PK) After Administration of DW6014 and Each Component in Healthy Adult Volunteers in Fed Condition.

DW6014

Korea, Republic of
AstraZeneca

Recruiting

A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK (ZEAL UNLOCK)

Liver Cirrhosis

Italy, Japan, Germany, Belgium, Poland, Australia, United States, United Kingdom, Czechia, Slovakia
Jinnah Postgraduate Medical Centre

Not yet recruiting

Efficacy of Empagliflozin and Pioglitazone in Diabetic Patients With NAFLD

Non-Alcoholic Fatty Liver Disease | Type2diabetes

Pakistan
Yangjin
Peking University Third Hospital

Not yet recruiting

Evaluation of the Safety and Efficacy of SGLT2 Inhibitors in Pre-diabetic Patients

Prediabetic State | Impaired Glucose Tolerance | Impaired Fasting Glucose

China
Miulli General Hospital

Not yet recruiting

Empagliflozin and Atrial Fibrillation Treatment (EMPA-AF)

Heart Failure | Obesity | Diabetes Mellitus | Atrial Fibrillation

Italy
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Fixed Dose Combination of Dapagliflozin/Metformin XR Relative to Co-administration of the Individual Components in Healthy Chinese Subjects.

Healthy Volunteer

China
McGill University Health Centre/Research Institute...

Recruiting

Empagliflozin in Acute Heart Failure (DRIP-AHF-1)

Chronic Kidney Diseases | Acute Heart Failure

Canada
Mount Sinai Hospital, Canada
Boehringer Ingelheim

Recruiting

Empagliflozin and the Preservation of Beta-cell Function in Women With Recent Gestational Diabetes (EMPA post-GDM)

Gestational Diabetes

Canada
Butler Hospital
National Institute of Mental Health (NIMH)

Completed

Antidepressant Medication for Reducing HIV Risk Behavior in Depressed Intravenous Drug Users

Substance-Related Disorders | Depression | HIV Infections

United States
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease (SLIDE)

NAFLD | Non-Alcoholic Fatty Liver Disease | Pediatric NAFLD

United States
AstraZeneca

Completed

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

Bioequivalence | Fixed Dose Combination Tablets | Healthy Male and Female Subjects

United States
Rehab Werida
University of Alexandria

Recruiting

Dapagliflozin in Type 2 Diabetes Mellitus Patients (T2DM) With Nonalcoholic Fatty Liver Disease (NAFLD)

Type 2 Diabetes | Nonalcoholic Fatty Liver Disease

Egypt
Tanta University

Not yet recruiting

Comparative Clinical Study Between Empagliflozin Versus Pioglitazone in Non-diabetic Patients With Non-alcoholic Steatohepatitis

Non Alcoholic Steatohepatitis

Egypt
The Affiliated Hospital of Qingdao University

Completed

Bioequivalence Study of Empagliflozin And Linagliptin Tablets in Healthy Chinese Subjects

Healthy

China
Matthieu Pelletier-Galarneau, MD MSc

Not yet recruiting

Suppression With Empagliflozin as an Alternative To High-Fat Low-Carbohydrate Diet for Myocardial F-fluorodeoxyglucose Positron Emission Tomography (FDG-PET) Imaging (SWEET-HEART)

Myocardial Suppression
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 690517 Alone or in Combination With Empagliflozin Improve Kidney Function in People With Chronic Kidney Disease

Kidney Disease, Chronic

United States, Spain, Korea, Republic of, Belgium, Australia, Hong Kong, India, Canada, China, Germany, Italy, Japan, Malaysia, Finland, Switzerland, Turkey, Hungary, Poland, Portugal, Philippines, Czechia, Greece, Bulgaria, Brazil, Arg... and more
Medical University of Graz
Medical University of Vienna; Johannes Kepler University of Linz; Paracelsus... and other collaborators

Completed

Impact of EMpagliflozin on Cardiac Function and Biomarkers of Heart Failure in Patients With Acute MYocardial Infarction (EMMY)

Acute Myocardial Infarction

Austria
Research Institute for Complex Problems of Cardiovascular...

Completed

Safety and Efficacy of Empagliflozin for Patients With Diabetes Mellitus and Planned Percutaneous Coronary Interventions (SAFARY)

Coronary Artery Disease | Diabetes Mellitus | Percutaneous Coronary Intervention
National University of Malaysia

Unknown

Effect of SGLT2 Inhibition on OCT-A Parameters in Diabetic CKD

Diabetes Mellitus | Chronic Kidney Diseases | Diabetic Retinopathy

Malaysia
Maastricht University Medical Center

Recruiting

Empagliflozin for Peripheral Microvascular Dysfunction in Heart Failure With Preserved Ejection Fraction

Heart Failure With Preserved Ejection Fraction | Microvascular Dysfunction

Netherlands
AstraZeneca

Completed

A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes (DERIVE)

Type 2 Diabetes Mellitus

United States, Italy, Spain, Sweden, Canada, Bulgaria, Poland, Czechia
University of Alabama at Birmingham

Not yet recruiting

Mechanistic Insights to Weight Loss Maintenance Through SGLT2 Inhibitors

Obesity | Weight Loss

United States
The University of Hong Kong

Recruiting

Stress Cardiac Magnetic Resonance of Asymptomatic Type 2 Diabetics With Cardiovascular High Risk to Measure Empagliflozin Impact on Myocardial Blood Flow (CATCH-EM) (CATCH-EM)

Type 2 Diabetes | Microvascular Coronary Artery Disease

Hong Kong
University Hospital Tuebingen

Withdrawn

Empagliflozin Effect on Glucose Toxicity

Type2 Diabetes Mellitus

Germany
AstraZeneca

Recruiting

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

Chronic Kidney Disease and Hypertension

Spain, United States, Argentina, Denmark, Italy, Sweden, United Kingdom, Belgium, France, Turkey, China, Germany, Saudi Arabia, Thailand, Vietnam, Australia, Serbia, Brazil, Canada, Japan, Malaysia, Philippines, Poland, Taiwan, Greece, Is... and more
Newsoara Biopharma Co., Ltd.

Recruiting

Safety and Efficacy of THR-1442 Compared to Dapagliflozin as Add-on Therapy to Metformin in T2DM

T2DM

China
University Health Network, Toronto

Recruiting

Efficacy, Mechanisms and Safety of SGLT2 Inhibitors in Kidney Transplant Recipients (INFINITI2019)

Type 2 Diabetes | Kidney Transplant Recipients | Post-transplant Diabetes Mellitus

Canada
National Taiwan University Hospital
Shin Kong Wu Ho-Su Memorial Hospital

Not yet recruiting

Empagliflozin in Heart Failure With Reduced Ejection Fraction and End Stage Renal Disease (EMPA-RRED)

Heart Failure With Reduced Ejection Fraction | End Stage Renal Disease on Dialysis
AstraZeneca

Recruiting

Efficacy of FDC Regimen of Dapagliflozin/Metformin Compared to Co-administered Dual Therapy on Glycemic Control, Satisfaction and Adherence in Chinese Patients With T2DM

Type 2 Diabetes Mellitus (T2DM)

China
Hannover Medical School

Terminated

Empagliflozin Reduces Progression of Diabetic Retinopathy in Patients With High Risk of Diabetic Macular Edema

Diabetes Mellitus, Type II

Germany
Nanjing First Hospital, Nanjing Medical University

Unknown

Therapeutic Effect of Dapagliflozin Combined With CSII on Newly Diagnosed Type 2 Diabetes Mellitus

Type 2 Diabetes Mellitus
Chungbuk National University Hospital

Completed

Head-to-head Comparison of Empagliflozin and Dapagliflozin

Type2 Diabetes

Korea, Republic of
Ain Shams University
Drug Research Centre, Cairo, Egypt

Completed

The Effect of Morning Versus Evening Administration on The Pharmacokinetics and Pharmacodynamics of Empagliflozin

Diabetes Mellitus | Pharmacokinetics | Pharmacodynamics

Egypt
The George Institute
Victor Chang Cardiac Research Institute; St Vincent's Centre for Applied Medical...

Recruiting

Polydiuretic Therapy for HFpEF, a Randomised Controlled Trial

Heart Failure With Preserved Ejection Fraction

Australia
Qingdao Central Hospital

Recruiting

The Effect of Dapagliflozin on the Short-term Prognosis of Patients With Acute Myocardial Infarction

Myocardial Infarction | Glucose Intolerance | Diabete Type 2

China
Saint Luke's Health System

Completed

Dapagliflozin in PRESERVED Ejection Fraction Heart Failure (PRESERVED-HF)

Chronic Heart Failure With Preserved Systolic Function

United States
Ann & Robert H Lurie Children's Hospital of Chicago

Not yet recruiting

Mechanisms of SGLT2 Inhibition in Pediatric Steatotic Liver Disease (SHIELD)

Non-Alcoholic Fatty Liver Disease

Search clinical trials for: Empagliflozin

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations